Unconfigured Ad

Collapse

Discussion of any scientific study related to high content or next generation genomics. Whole genome association, metagenomics, digital gene expression, etc.

Forums Topics Posts Last Post
No forums found.
  •  
  • Filter
  • Time
  • Answered
  • Show
  • New Topics
Clear All
new posts
There are no conversations in this channel.
 
  • Filter
  • Time
  • Show
Clear All
new posts
Please log in to your account to view your subscribed posts.
  •  
  • Filter
  • Time
  • Answered
  • Show
  • Sort By
  • Order
Clear All
new posts
Topics Statistics Last Post
Started by steven, 03-11-2010, 04:21 AM
10 responses
34,013 views
0 reactions
Last Post ECO
by ECO
 
Started by tedwong, 08-14-2016, 06:51 PM
7 responses
12,347 views
0 reactions
Last Post tedwong
by tedwong
 
Started by GenoMax, 08-09-2016, 07:53 AM
3 responses
10,359 views
0 reactions
Last Post tedwong
by tedwong
 
Started by tedwong, 08-14-2016, 05:40 PM
0 responses
9,112 views
0 reactions
Last Post tedwong
by tedwong
 
Started by Strandlife, 07-03-2016, 10:11 PM
0 responses
8,842 views
0 reactions
Last Post Strandlife  
Started by edeka, 06-13-2016, 01:54 AM
0 responses
8,581 views
0 reactions
Last Post edeka
by edeka
 
Started by m_elena_bioinfo, 03-23-2016, 02:06 AM
Started by etal, 10-30-2014, 02:48 PM
41 responses
41,517 views
0 reactions
Last Post oxydeepu  
Started by Newsbot!, 08-28-2012, 02:00 AM
8 responses
19,236 views
0 reactions
Last Post TPH
by TPH
 
Started by Newsbot!, 06-07-2011, 02:00 AM
19 responses
18,196 views
0 reactions
Last Post Maflores11  
Started by Joann, 02-24-2016, 08:21 AM
0 responses
7,738 views
0 reactions
Last Post Joann
by Joann
 
No topics found.
  • Filter
  • Time
Clear All
widgetinstance 229 (Webinars) skipped due to lack of content & hide_module_if_empty option.

Recent Articles

Collapse

  • SEQadmin2
    Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
    by SEQadmin2


    Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

    The systematic characterization of the human proteome has
    ...
    Today, 11:48 AM
  • SEQadmin2
    Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
    by SEQadmin2



    Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
    ...
    07-09-2026, 11:10 AM
  • SEQadmin2
    Cancer Drug Resistance: The Lingering Barrier to Rising Survival
    by SEQadmin2



    Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

    There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
    07-08-2026, 05:17 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, Today, 11:10 AM
0 responses
8 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-13-2026, 10:26 AM
0 responses
30 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-09-2026, 10:04 AM
0 responses
38 views
0 reactions
Last Post SEQadmin2  
Working...